ArticleObesity surgery2026
Does Bariatric Surgery Improve Lymphedema? A Scoping Review.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a recognized risk factor for lymphatic dysfunction and lymphedema, yet the burden of lymphatic disease among populations undergoing Metabolic Bariatric Surgery (MBS) and the impact of MBS on established lymphedema remain unclear. We conducted a scoping review in accordance with PRISMA-ScR guidelines, searching PubMed, ClinicalKey, and the Cochrane Library for studies evaluating lymphatic disease in bariatric populations or reporting lymphedema-related outcomes following MBS. Six studies met the inclusion criteria, consisting primarily of case reports and small case series. MBS was variably associated with reductions in limb volume and symptom burden; however, objective physiologic assessments frequently demonstrated persistent lymphatic dysfunction despite substantial weight loss. Current evidence suggests MBS may provide clinical improvement in selected patients but should be considered an adjunct rather than a definitive treatment for lymphedema, highlighting the need for prospective studies with standardized outcomes.
Indexed as
Identifiers
42185712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.